| pubmed-article:12217805 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12217805 | lifeskim:mentions | umls-concept:C0008972 | lld:lifeskim |
| pubmed-article:12217805 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12217805 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:12217805 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:12217805 | lifeskim:mentions | umls-concept:C0077973 | lld:lifeskim |
| pubmed-article:12217805 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:12217805 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:12217805 | lifeskim:mentions | umls-concept:C0179926 | lld:lifeskim |
| pubmed-article:12217805 | lifeskim:mentions | umls-concept:C0205088 | lld:lifeskim |
| pubmed-article:12217805 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:12217805 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:12217805 | pubmed:dateCreated | 2002-9-9 | lld:pubmed |
| pubmed-article:12217805 | pubmed:abstractText | In the absence of a cure for multiple myeloma (MM) with standard-dose therapy, any strategy that can be expected to increase tumor reduction and to extend survival duration is likely to be of clinical relevance. The primary end-point of the present study was to investigate whether the alternating combination of vincristine-doxorubicin-dexamethasone (VAD) and melphalan-prednisone (MP) or vincristine-mitoxantrone-dexamethasone (VND) and MP could improve the clinical outcome of MM patients thus treated in comparison with those receiving MP alone. | lld:pubmed |
| pubmed-article:12217805 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12217805 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12217805 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12217805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12217805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12217805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12217805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12217805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12217805 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12217805 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12217805 | pubmed:issn | 0390-6078 | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:BaccaraniMich... | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:TuraSanteS | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:FiacchiniMaur... | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:TosiPatriziaP | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:CavoMicheleM | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:ZamagniElenaE | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:CelliniClaudi... | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:RonconiSoniaS | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:BenniMonicaM | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:GozzettiAless... | lld:pubmed |
| pubmed-article:12217805 | pubmed:author | pubmed-author:Writing... | lld:pubmed |
| pubmed-article:12217805 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12217805 | pubmed:volume | 87 | lld:pubmed |
| pubmed-article:12217805 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12217805 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12217805 | pubmed:pagination | 934-42 | lld:pubmed |
| pubmed-article:12217805 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:meshHeading | pubmed-meshheading:12217805... | lld:pubmed |
| pubmed-article:12217805 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12217805 | pubmed:articleTitle | Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. | lld:pubmed |
| pubmed-article:12217805 | pubmed:affiliation | Institute of Hematology and Medical Oncology Seràgnoli, via Massarenti 9, 40138 Bologna, Italy. mcavo@med.unibo.it | lld:pubmed |
| pubmed-article:12217805 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12217805 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12217805 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:12217805 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12217805 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12217805 | lld:pubmed |
